NCT00300742

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Virginia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the feasibility of using topiramate to reduce binge eating and drinking episodes in alcohol dependent individuals with comorbid binge eating disorder.

Detailed description

Research has shown an alarming coincidence of binge eaters also reporting serious alcohol abuse. Evidence has shown this population to have higher rates of psychiatric comorbidity, higher caloric intakes during meals, higher rates of tobacco use, more frequent binge episodes, and an earlier age of onset for binge eating and alcohol abuse. It is believed that topiramate may reduce binge eating and has been found helpful in reducing the cravings associated with alcohol consumption. This study is to test the feasibility of administering topiramate to individuals with alcohol dependence and binge eating disorder. This will involve determining the adequacy of the amount of assessment and scheduled visits.

Conditions

• Alcohol Dependence
• Binge Eating

Interventions

Type	Name	Description
DRUG	Topiramate	Topiramate up to 300 mg per day.

Timeline

• Start date: 2006-03-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2006-03-09
• Last updated: 2017-07-12
• Results posted: 2017-05-11

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study